Suppr超能文献

使用复方口服避孕药进行周期调控对与子宫内膜容受性相关的基因表达的影响。

The impact of using the combined oral contraceptive pill for cycle scheduling on gene expression related to endometrial receptivity.

机构信息

Instituto Valenciano de Infertilidad, Av. Del Talgo 68 (28023), Madrid, Spain.

出版信息

Hum Reprod. 2014 Jun;29(6):1271-8. doi: 10.1093/humrep/deu065. Epub 2014 Apr 4.

Abstract

STUDY QUESTION

Does the combined oral contraceptive pill (COCP) change endometrial gene expression when used for cycle programming?

SUMMARY ANSWER

COCP used for scheduling purposes does not have a significant impact on endometrial gene expression related to endometrial receptivity.

WHAT IS KNOWN ALREADY

Controversy exists around COCP pretreatment for IVF cycle programming, as some authors claim that it might be detrimental to the live birth rate. Microarray technology applied to the study of tissue gene expression has previously revealed the behavior of genes related to endometrial receptivity under different conditions.

STUDY DESIGN, SIZE, AND DURATION: Proof-of-concept study of 10 young healthy oocyte donors undergoing controlled ovarian stimulation (COS) recruited between June 2012 and February 2013.

PARTICIPANTS/MATERIALS, SETTING, AND METHODS: Microarray data were obtained from endometrial biopsies from 10 young healthy oocyte donors undergoing COS with GnRH antagonists and recombinant FSH. In group A (n = 5), COCP pretreatment was used for 12-16 days, and stimulation began after a 5-day pill-free interval. Stimulation in group B (n = 5) was initiated on cycle day 3 after a spontaneous menses. Endometrial biopsies were collected 7 days after triggering with hCG.

MAIN RESULTS AND THE ROLE OF CHANCE

No individual genes exhibited increased or decreased expression (fold change (FC) >2) in patients with prior COCP treatment (group A) compared with controls (group B). However, the results of the functional analysis showed a total of 11 biological processes that were significantly enriched in group A compared with group B (non-COCP).

LIMITATIONS, REASONS FOR CAUTION: The Endometrial Receptivity Array (ERA) has only been validated on endometrial samples obtained in natural cycles and after hormonal replacement treatment (HRT). Therefore, it was not possible in this study to classify the endometrial samples as receptive or non-receptive. We used the ERA to focus on 238 genes that are intimately related to endometrial receptivity, thus simplifying the analysis and understanding of the data.

WIDER IMPLICATIONS OF THE FINDINGS

Cycle scheduling is common in IVF units and is used to avoid weekend retrievals and/or to distribute evenly the workload for better efficiency. Our failure to detect any relevant changes in the genes related to the window of implantation when cycles were programmed with COCP pretreatment suggests that, despite controversial clinical results in previous studies, the use of COCPs in this way does not affect uterine receptivity adversely.

STUDY FUNDING/COMPETING INTEREST(S): Funding for this study was provided by an unrestricted grant from Merck Sharp & Dohme. C.S. and A.P. are co-inventors (with Patricia Diaz-Gimeno) of the Endometrial Receptivity Array and hold the patent. The other authors have no conflicts of interest to declare.

TRIAL REGISTRATION NUMBER

EudraCT registration number is 2011-003250-34.

摘要

研究问题

口服避孕药(COCP)用于周期调控时是否会改变子宫内膜基因表达?

总结答案

用于调控周期的 COCP 对与子宫内膜容受性相关的子宫内膜基因表达没有显著影响。

已知情况

一些作者声称 COCP 预处理可能对活产率有害,因此围绕 IVF 周期调控中 COCP 预处理存在争议。应用于组织基因表达研究的微阵列技术先前揭示了在不同条件下与子宫内膜容受性相关的基因的行为。

研究设计、大小和持续时间:这是一项 2012 年 6 月至 2013 年 2 月期间招募的 10 名年轻健康卵母细胞供体进行控制性卵巢刺激(COS)的概念验证研究。

参与者/材料、地点和方法:从 10 名接受 GnRH 拮抗剂和重组 FSH 治疗的年轻健康卵母细胞供体的 COS 子宫内膜活检中获得微阵列数据。在 A 组(n = 5)中,使用 COCP 预处理 12-16 天,停药 5 天后开始刺激。B 组(n = 5)在自然月经后第 3 天开始刺激。用 hCG 触发后 7 天采集子宫内膜活检。

主要结果和机会的作用

与对照组(B 组)相比,接受 COCP 治疗(A 组)的患者中没有单个基因表现出表达增加或减少(倍数变化(FC)>2)。然而,功能分析的结果显示,与 B 组相比,A 组共有 11 个生物学过程显著富集(非 COCP)。

局限性、谨慎的原因:子宫内膜容受性阵列(ERA)仅在自然周期和激素替代治疗(HRT)获得的子宫内膜样本上得到验证。因此,在这项研究中,我们无法将子宫内膜样本分类为有接受能力或无接受能力。我们使用 ERA 专注于 238 个与子宫内膜容受性密切相关的基因,从而简化了分析和对数据的理解。

研究结果的更广泛意义

在 IVF 单位中,周期调度很常见,用于避免周末采集和/或均匀分配工作量以提高效率。当使用 COCP 预处理来安排周期时,我们未能检测到与着床窗口期相关的基因发生任何相关变化,这表明尽管之前的研究存在有争议的临床结果,但以这种方式使用 COCP 不会对子宫接受能力产生不利影响。

研究资金/利益冲突:这项研究的资金由默克夏普和多姆公司提供的一项不受限制的赠款提供。C.S. 和 A.P. 是子宫内膜容受性阵列的共同发明者(与 Patricia Diaz-Gimeno 一起),并拥有该专利。其他作者没有利益冲突需要声明。

临床试验注册号

EudraCT 注册号为 2011-003250-34。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验